Résultats de la recherche - 11 results
Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
detection and separate identification of 14 hrHPV types. Here, we present the clinical validation of the test in SurePath samples in comparison to a clinically validated reference test, the GP5 +/6+Enzyme ...
Assessment of the clinical and analytical performance of the Aptima SARS-CoV-2 assay using the VALCOR protocol.
a study protocol designed to set up a framework for test validation of SARS-CoV-2 virus assays. Using clinical samples collated from VALCOR, the performance of Aptima SARS-CoV-2 assay was assessed against ...
Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
cervical cancer screening should be clinically validated according to international criteria. OncoPredict HPV ® Screening (SCR) is a partial genotyping multiplex real-time PCR assay targeting E6 / E7 genes ...
Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Cervical Neoplasms Abstract: In 2012, VAL idation of human papillomavirus (HPV) GEN otyping T ests (VALGENT) was initiated to provide a formalized and uniform study framework for comparison and validation of ...
Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Tests) and aims to determine whether the reproducibility of Xpert HPV is in line with international validation criteria. METHODS Validation of new hrHPV DNA assays requires demonstration of good ...
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
evidence that the relative accuracy of HPV-testing on self- vs clinician-samples is robust across clinical settings, the VALHUDES protocol offers a framework for validation of HPV assay/self-sample device ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
Neoplasms Abstract: In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping performance of the INNO-LiPA HPV Genotyping II (INNO-LiPA) within the VALGENT-3 framework. ...
Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program.
with further follow-up. Validated PCR-based assays, detecting high-risk HPV DNA, are as accurate on self-samples as on clinician-collected samples. On the contrary, HPV assays, based on signal ...
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
countries are in the process of switching to high-risk human papillomavirus (hrHPV) testing for cervical cancer screening. Given the multitude of available tests, validated assays which assure high-quality ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
Oligonucleotide Probes Papillomaviridae Papillomavirus Infections Reference Standards Sensitivity and Specificity Young adult Abstract: The LMNX genotyping kit HPV GP (LMNX) is based on the clinically validated GP5 ...